AI-Powered Biotech Firm Earendil Labs Eyes HK IPO with Up to HK$3.9 Billion Fundraise

Viewpoint News:On March 13, capital market news reported that Earendil Labs, a biotech startup utilizing artificial intelligence for drug discovery, is considering an IPO in Hong Kong and is in discussions withCICCMorgan Stanley has begun arranging stock offerings, with a financing scale potentially reaching up to $500 million (approximately HK$3.9 billion).

Currently, Earendil, CICC, and Morgan Stanley have not responded to requests for comment.

Information shows that Earendil Labs, headquartered in Delaware, USA, is an affiliate of Beijing Huashen Zhiyao. By integrating machine learning, generative protein engineering, and high-throughput experimental technologies, the company is committed to biopharmaceutical R&D, focusing on next-generation innovative biologics for treating autoimmune diseases, cancer, and other unmet medical needs.

According to reports, Earendil Labs maintains partnerships with companies such as French pharmaceutical giant Sanofi, including a collaboration project on autoimmune and inflammatory diseases announced in January 2026. Additionally, Earendil reached an agreement with WuXi XDC last month regarding cancer therapy technology and announced another collaboration with WuXi Biologics on Thursday.

Disclaimer: The content and data in this article are organized by the author based on publicly available information, and do not constitute investment advice. Please verify before use.